» Articles » PMID: 38541221

Disseminated Enterovirus Infection in a Patient Affected by Follicular Lymphoma Treated with Obinutuzumab: A Case Report and a Narrative Review of the Literature

Overview
Publisher MDPI
Specialty General Medicine
Date 2024 Mar 28
PMID 38541221
Authors
Affiliations
Soon will be listed here.
Abstract

: the principal purpose of this literature review is to cluster adults with hematological malignancies after treatment or on maintenance with obinutuzumab who experienced disseminated EV infection to understand clinical characteristics and outcome of this rare condition in these patients. We report the first clinical case of a male affected by follicular lymphoma treated with immune-chemotherapy including obinutuzumab who was affected by disseminated EV infection with cardiovascular involvement. : this narrative review summarizes all the research about disseminated EV infection in immunosuppressed adult patients treated with obinutuzumab from January 2000 to January 2024 using the Scale for the Assessment of Narrative Review Articles (SANRA) flow-chart. We performed a descriptive statistic using the standard statistical measures for quantitative data. : we included six studies, five case reports, and one case report with literature analysis. We collected a total of seven patients, all female, with disseminated EV infection. The most common signs and clinical presentations of EV infection were fever and encephalitis symptoms (N = 6, 85.7%), followed by hepatitis/acute liver failure (N = 5, 71.4%). : onco-hematological patients who receive immune-chemotherapy with a combination of treatments which depress adaptative immunity, which includes the antiCD20 obinutuzumab, could be at higher risk of disseminated EV infection, including CNS and cardiac involvement.

Citing Articles

Cefiderocol for the Treatment of Nosocomial Bloodstream Infections Caused by Stenotrophomonas maltophilia: A Case Series and Literature Review.

Vena A, Mezzogori L, Castaldo N, Corcione S, Pascale R, Giannella M Infect Dis Ther. 2025; .

PMID: 40032812 DOI: 10.1007/s40121-025-01117-2.

References
1.
Amitai I, Gafter-Gvili A, Shargian-Alon L, Raanani P, Gurion R . Obinutuzumab-related adverse events: A systematic review and meta-analysis. Hematol Oncol. 2020; 39(2):215-221. DOI: 10.1002/hon.2828. View

2.
Kennedy P . An overview of viral infections of the nervous system in the immunosuppressed. J Neurol. 2020; 268(8):3026-3030. PMC: 7552955. DOI: 10.1007/s00415-020-10265-z. View

3.
McNeil T, Hannah R, Hui C, Qiao M . Disseminated enterovirus infection in a patient treated with obinutuzumab. J Med Virol. 2021; 94(2):439-441. DOI: 10.1002/jmv.27370. View

4.
Heger J, Eichenauer D, Kasper P, Boll B, Shimabukuro-Vornhagen A, Kochanek M . Fatal disseminated enterovirus infection in a patient with follicular lymphoma undergoing obinutuzumab maintenance therapy. Eur J Haematol. 2019; 103(3):268-271. DOI: 10.1111/ejh.13278. View

5.
Dunn J . Enteroviruses and Parechoviruses. Microbiol Spectr. 2016; 4(3). DOI: 10.1128/microbiolspec.DMIH2-0006-2015. View